ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Direct Indexing
    • Disruptive Technology
    • Energy Infrastructure
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Financial Literacy
    • Fixed Income
    • Gold/Silver/Critical Minerals
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Modern Alpha
    • Multifactor
    • Night Effect
    • Portfolio Strategies
    • Responsible Investing
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
  • Research
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF of the Week Podcast
    • ETF Prime Podcast
    • Video
  • Company
    • About VettaFi
    • Get VettaFi’ed
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Disruptive Technology Channel
  2. Cancer Detection & Investment Selection: The ARKG ETF
Disruptive Technology Channel
Share

Cancer Detection & Investment Selection: The ARKG ETF

Tom LydonJan 08, 2021
2021-01-08

The ARK Genomic Revolution Multi-Sector Fund (ARKG A-) isn’t just one of the best actively managed exchange traded funds. Nor is it just one of the best healthcare ETFs. It’s one of the premier options for investors looking for a truly disruptive play on healthcare investing.

Disruptive technologies are changing the way new products and services are being brought to market, already seen in the development of artificial intelligence and robotics. As the number of companies that focus on highly advanced computer integration grows, so does the number of targeted ETF strategies that have been designed to capture the best growth opportunities.

One of the frontiers some ARKG components are forging into is early detection of cancer, which can save billions of dollars and, more importantly, lives.

“Cancer is easier to treat when diagnosed early. All solid tumors start as benign lesions called neoplasia that advance from local, to regional, and finally to distant or metastatic cancer,” notes ARK analyst Simon Barnett. “As cancer progresses, the number of treatment options shrinks. Surgeons lose the ability to remove tumors completely and chemotherapies become ineffective. Unfortunately for many patients, symptoms don’t present until their cancers have spread.”

ARKG 1 Year Performance

ARKG: A Credible Early Detection Bet

When it comes to early detection as an investable concept, ARKG’s forward-looking methodology is an advantage many rival funds don’t have.

“Securities within ARKG are substantially focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business. One such way this is accomplished is by offering new products or services that rely on genomic sequencing, analysis, synthesis or instrumentation,” according to the issuer.

Today, many legacy cancer detection systems and tools are decades old. ARKG components are changing that.

“In the face of our analysis that multi-cancer liquid biopsy screening could lower cancer-specific deaths by 66,000 per year, we also understand the obstacles to widespread adoption in the near term. While some companies in the space may pursue near-term commercialization, we do not expect FDA approval nor reimbursement to occur until at least 2023,” notes Barnett.

For more on disruptive technologies, visit our Disruptive Technology Channel.


Content continues below advertisement

Loading Articles...
Our Sites
  • VettaFi
  • Advisor Perspectives
  • ETF Trends
Tools
  • ETF Screener
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Database Pro
More Tools
  • Financial Advisor & RIA Center
Explore ETFs
  • ETF News
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Information
  • Contact Us
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X